Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

Alexandra B. Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Enkeleida Nikaï, Baojin Zhu, Emily Edson-Heredia, Hilde Carlier, Chen Yen Lin, Orin Goldblum, Gil Yosipovitch

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background Itch is a prevalent symptom of psoriasis that impacts quality of life. Objective We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3). Methods The itch numeric rating scale evaluated psoriasis itch severity in all 3 trials. Skin pain was assessed by skin pain visual analog scale. Bothersomeness because of redness/discoloration, thickness, and scaling/flaking was assessed with the Psoriasis Skin Appearance Bothersomeness instrument. Psoriasis skin appearance bothersomeness and skin pain were assessed at baseline and week 12; itch numeric rating scale score was assessed at baseline and weeks 1, 2, 4, 8, and 12. Results Patients who received ixekizumab demonstrated statistically significant improvements (P < .001) in itch severity, reduction in skin pain, and degree of bothersomeness compared with those who received etanercept or placebo. Clinically meaningful improvements in itch severity were achieved as early as week 1. Limitations Longer-term evaluations of psoriasis symptom improvement with ixekizumab treatment are needed. Conclusion After treatment with ixekizumab, patients reported fast, significant, and clinically meaningful improvements in itch severity and other psoriasis-related symptoms such as skin pain and skin appearance bothersomeness.

Original languageEnglish (US)
Pages (from-to)1156-1161
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume75
Issue number6
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

LY2439821
Phase III Clinical Trials
Psoriasis
Skin
Pain
Placebos
Symptom Assessment

Keywords

  • itch
  • itch numeric rating scale
  • patient-reported outcomes
  • psoriasis
  • skin appearance bothersomeness
  • skin pain

ASJC Scopus subject areas

  • Dermatology

Cite this

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms : Results from 3 phase III psoriasis clinical trials. / Kimball, Alexandra B.; Luger, Thomas; Gottlieb, Alice; Puig, Luis; Kaufmann, Roland; Nikaï, Enkeleida; Zhu, Baojin; Edson-Heredia, Emily; Carlier, Hilde; Lin, Chen Yen; Goldblum, Orin; Yosipovitch, Gil.

In: Journal of the American Academy of Dermatology, Vol. 75, No. 6, 01.12.2016, p. 1156-1161.

Research output: Contribution to journalArticle

Kimball, AB, Luger, T, Gottlieb, A, Puig, L, Kaufmann, R, Nikaï, E, Zhu, B, Edson-Heredia, E, Carlier, H, Lin, CY, Goldblum, O & Yosipovitch, G 2016, 'Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials', Journal of the American Academy of Dermatology, vol. 75, no. 6, pp. 1156-1161. https://doi.org/10.1016/j.jaad.2016.07.034
Kimball, Alexandra B. ; Luger, Thomas ; Gottlieb, Alice ; Puig, Luis ; Kaufmann, Roland ; Nikaï, Enkeleida ; Zhu, Baojin ; Edson-Heredia, Emily ; Carlier, Hilde ; Lin, Chen Yen ; Goldblum, Orin ; Yosipovitch, Gil. / Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms : Results from 3 phase III psoriasis clinical trials. In: Journal of the American Academy of Dermatology. 2016 ; Vol. 75, No. 6. pp. 1156-1161.
@article{ee519ddf0d634e0891090cb818c39276,
title = "Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials",
abstract = "Background Itch is a prevalent symptom of psoriasis that impacts quality of life. Objective We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3). Methods The itch numeric rating scale evaluated psoriasis itch severity in all 3 trials. Skin pain was assessed by skin pain visual analog scale. Bothersomeness because of redness/discoloration, thickness, and scaling/flaking was assessed with the Psoriasis Skin Appearance Bothersomeness instrument. Psoriasis skin appearance bothersomeness and skin pain were assessed at baseline and week 12; itch numeric rating scale score was assessed at baseline and weeks 1, 2, 4, 8, and 12. Results Patients who received ixekizumab demonstrated statistically significant improvements (P < .001) in itch severity, reduction in skin pain, and degree of bothersomeness compared with those who received etanercept or placebo. Clinically meaningful improvements in itch severity were achieved as early as week 1. Limitations Longer-term evaluations of psoriasis symptom improvement with ixekizumab treatment are needed. Conclusion After treatment with ixekizumab, patients reported fast, significant, and clinically meaningful improvements in itch severity and other psoriasis-related symptoms such as skin pain and skin appearance bothersomeness.",
keywords = "itch, itch numeric rating scale, patient-reported outcomes, psoriasis, skin appearance bothersomeness, skin pain",
author = "Kimball, {Alexandra B.} and Thomas Luger and Alice Gottlieb and Luis Puig and Roland Kaufmann and Enkeleida Nika{\"i} and Baojin Zhu and Emily Edson-Heredia and Hilde Carlier and Lin, {Chen Yen} and Orin Goldblum and Gil Yosipovitch",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jaad.2016.07.034",
language = "English (US)",
volume = "75",
pages = "1156--1161",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms

T2 - Results from 3 phase III psoriasis clinical trials

AU - Kimball, Alexandra B.

AU - Luger, Thomas

AU - Gottlieb, Alice

AU - Puig, Luis

AU - Kaufmann, Roland

AU - Nikaï, Enkeleida

AU - Zhu, Baojin

AU - Edson-Heredia, Emily

AU - Carlier, Hilde

AU - Lin, Chen Yen

AU - Goldblum, Orin

AU - Yosipovitch, Gil

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Itch is a prevalent symptom of psoriasis that impacts quality of life. Objective We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3). Methods The itch numeric rating scale evaluated psoriasis itch severity in all 3 trials. Skin pain was assessed by skin pain visual analog scale. Bothersomeness because of redness/discoloration, thickness, and scaling/flaking was assessed with the Psoriasis Skin Appearance Bothersomeness instrument. Psoriasis skin appearance bothersomeness and skin pain were assessed at baseline and week 12; itch numeric rating scale score was assessed at baseline and weeks 1, 2, 4, 8, and 12. Results Patients who received ixekizumab demonstrated statistically significant improvements (P < .001) in itch severity, reduction in skin pain, and degree of bothersomeness compared with those who received etanercept or placebo. Clinically meaningful improvements in itch severity were achieved as early as week 1. Limitations Longer-term evaluations of psoriasis symptom improvement with ixekizumab treatment are needed. Conclusion After treatment with ixekizumab, patients reported fast, significant, and clinically meaningful improvements in itch severity and other psoriasis-related symptoms such as skin pain and skin appearance bothersomeness.

AB - Background Itch is a prevalent symptom of psoriasis that impacts quality of life. Objective We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3). Methods The itch numeric rating scale evaluated psoriasis itch severity in all 3 trials. Skin pain was assessed by skin pain visual analog scale. Bothersomeness because of redness/discoloration, thickness, and scaling/flaking was assessed with the Psoriasis Skin Appearance Bothersomeness instrument. Psoriasis skin appearance bothersomeness and skin pain were assessed at baseline and week 12; itch numeric rating scale score was assessed at baseline and weeks 1, 2, 4, 8, and 12. Results Patients who received ixekizumab demonstrated statistically significant improvements (P < .001) in itch severity, reduction in skin pain, and degree of bothersomeness compared with those who received etanercept or placebo. Clinically meaningful improvements in itch severity were achieved as early as week 1. Limitations Longer-term evaluations of psoriasis symptom improvement with ixekizumab treatment are needed. Conclusion After treatment with ixekizumab, patients reported fast, significant, and clinically meaningful improvements in itch severity and other psoriasis-related symptoms such as skin pain and skin appearance bothersomeness.

KW - itch

KW - itch numeric rating scale

KW - patient-reported outcomes

KW - psoriasis

KW - skin appearance bothersomeness

KW - skin pain

UR - http://www.scopus.com/inward/record.url?scp=84996558160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996558160&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2016.07.034

DO - 10.1016/j.jaad.2016.07.034

M3 - Article

C2 - 27692498

AN - SCOPUS:84996558160

VL - 75

SP - 1156

EP - 1161

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -